为了探讨胸腺嘧啶标记指数(LI)和乳癌长期.预后的关系,作者对128例乳癌患者进行了长达10年之久的观察和分析.标本取自128例第一次治疗的原发乳癌患者;其中96个标本来源于手术,32个来源于穿刺活检。将~3H标记的胸腺嘧啶和标本在体外一起培养后,测定瘤组织的LI.所有患者在治疗前分成三组:Ⅰ组: LI<0.25;Ⅱ组:0.25≤LI<3.84;Ⅲ组:LI>3.84。治疗方法:单纯手术,单纯放疗,肿瘤组织大于7 cm 者,采用术前放疗及手术切除肿瘤。患者接受 To investigate the relationship between the thymidine labeling index (LI) and the long-term prognosis of breast cancer, the authors observed and analyzed 128 cases of breast cancer for up to 10 years. The samples were taken from 128 primary breast cancer patients who were treated for the first time. Of these, 96 were from surgery and 32 from biopsy. After the ~3H-labeled thymidine was incubated with the specimen in vitro, the tumor tissue was measured for LI. All patients were divided into three groups before treatment: Group I: LI <0.25; Group II: 0.25

3.84. Treatment methods: surgery alone, radiotherapy alone, tumor tissue greater than 7 cm, preoperative radiotherapy and surgical removal of the tumor. Patient acceptance